HEADER ANDROGEN RECEPTOR 27-DEC-01 1GS4 TITLE STRUCTURAL BASIS FOR THE GLUCOCORTICOID RESPONSE IN A MUTANT HUMAN TITLE 2 ANDROGEN RECEPTOR (ARCCR) DERIVED FROM AN ANDROGEN-INDEPENDENT TITLE 3 PROSTATE CANCER COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANDROGEN RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: LIGAND-BINDING DOMAIN, RESIDUES 670-917; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008 KEYWDS ANDROGEN RECEPTOR, HUMAN ANDROGEN RECEPTOR, LIGAND-BINDING DOMAIN, KEYWDS 2 CORTISOL/ CORTISONE RESPONSE, PROSTATE CANCER EXPDTA X-RAY DIFFRACTION AUTHOR P.M.MATIAS,M.A.CARRONDO,R.COELHO,M.THOMAZ,X.-Y.ZHAO,A.WEGG,K.CRUSIUS, AUTHOR 2 U.EGNER,P.DONNER REVDAT 3 28-FEB-18 1GS4 1 SOURCE JRNL REMARK ATOM REVDAT 2 24-FEB-09 1GS4 1 VERSN REVDAT 1 16-JAN-03 1GS4 0 JRNL AUTH P.M.MATIAS,M.A.CARRONDO,R.COELHO,M.THOMAZ,X.-Y.ZHAO,A.WEGG, JRNL AUTH 2 K.CRUSIUS,U.EGNER,P.DONNER JRNL TITL STRUCTURAL BASIS FOR THE GLUCOCORTICOID RESPONSE IN A MUTANT JRNL TITL 2 HUMAN ANDROGEN RECEPTOR (AR(CCR)) DERIVED FROM AN JRNL TITL 3 ANDROGEN-INDEPENDENT PROSTATE CANCER JRNL REF J.MED.CHEM. V. 45 1439 2002 JRNL REFN ISSN 0022-2623 JRNL PMID 11906285 JRNL DOI 10.1021/JM011072J REMARK 2 REMARK 2 RESOLUTION. 1.95 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 21.50 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM 5% SUBSET REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.205 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.285 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 998 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 20504 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.197 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.272 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 844 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 17716 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1993 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 106 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 2083.0 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 1 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 8549 REMARK 3 NUMBER OF RESTRAINTS : 8331 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 ANGLE DISTANCES (A) : 0.020 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : NULL REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.019 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.027 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.035 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.150 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : NULL REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.073 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1GS4 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 27-DEC-01. REMARK 100 THE DEPOSITION ID IS D_1290009175. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-APR-01 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.20 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : DIAMOND(111)+GE(220) REMARK 200 OPTICS : TOROIDAL MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20504 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.950 REMARK 200 RESOLUTION RANGE LOW (A) : 21.500 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.04500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 18.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.95 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.00 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.60 REMARK 200 R MERGE FOR SHELL (I) : 0.26600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 4.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1E3G REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.36 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.20 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.17500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 36.52500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 33.11500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 36.52500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.17500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 33.11500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED MUTATIONS: LEU (491) HIS, THR (667) ALA REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LYS A 847 REMARK 465 ASN A 848 REMARK 465 PRO A 849 REMARK 465 THR A 850 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 670 CG CD OE1 NE2 REMARK 470 ASN A 727 CG OD1 ND2 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLN A 670 CB REMARK 480 ASN A 692 OD1 ND2 REMARK 480 LYS A 720 CD CE NZ REMARK 480 VAL A 730 CG2 REMARK 480 LYS A 836 CG CD CE NZ REMARK 480 ARG A 846 NH1 NH2 REMARK 480 LYS A 883 NZ REMARK 480 GLU A 897 CD OE1 OE2 REMARK 480 HIS A 917 OXT REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD1 ASP A 690 ND2 ASN A 692 1.65 REMARK 500 OD2 ASP A 690 ND2 ASN A 692 2.03 REMARK 500 CG ASP A 690 ND2 ASN A 692 2.09 REMARK 500 O HIS A 689 O HOH A 2017 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 843 0.18 -66.87 REMARK 500 HIS A 885 9.15 -64.45 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 A1919 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ZK5 A1918 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1E3G RELATED DB: PDB REMARK 900 HUMAN ANDROGEN RECEPTOR LIGAND BINDING IN COMPLEX WITH THE LIGAND REMARK 900 METRIBOLONE (R1881) DBREF 1GS4 A 670 917 UNP P10275 ANDR_HUMAN 670 917 SEQADV 1GS4 HIS A 701 UNP P49699 LEU 701 ENGINEERED MUTATION SEQADV 1GS4 ALA A 877 UNP P49699 THR 877 ENGINEERED MUTATION SEQRES 1 A 248 GLN PRO ILE PHE LEU ASN VAL LEU GLU ALA ILE GLU PRO SEQRES 2 A 248 GLY VAL VAL CYS ALA GLY HIS ASP ASN ASN GLN PRO ASP SEQRES 3 A 248 SER PHE ALA ALA LEU HIS SER SER LEU ASN GLU LEU GLY SEQRES 4 A 248 GLU ARG GLN LEU VAL HIS VAL VAL LYS TRP ALA LYS ALA SEQRES 5 A 248 LEU PRO GLY PHE ARG ASN LEU HIS VAL ASP ASP GLN MET SEQRES 6 A 248 ALA VAL ILE GLN TYR SER TRP MET GLY LEU MET VAL PHE SEQRES 7 A 248 ALA MET GLY TRP ARG SER PHE THR ASN VAL ASN SER ARG SEQRES 8 A 248 MET LEU TYR PHE ALA PRO ASP LEU VAL PHE ASN GLU TYR SEQRES 9 A 248 ARG MET HIS LYS SER ARG MET TYR SER GLN CYS VAL ARG SEQRES 10 A 248 MET ARG HIS LEU SER GLN GLU PHE GLY TRP LEU GLN ILE SEQRES 11 A 248 THR PRO GLN GLU PHE LEU CYS MET LYS ALA LEU LEU LEU SEQRES 12 A 248 PHE SER ILE ILE PRO VAL ASP GLY LEU LYS ASN GLN LYS SEQRES 13 A 248 PHE PHE ASP GLU LEU ARG MET ASN TYR ILE LYS GLU LEU SEQRES 14 A 248 ASP ARG ILE ILE ALA CYS LYS ARG LYS ASN PRO THR SER SEQRES 15 A 248 CYS SER ARG ARG PHE TYR GLN LEU THR LYS LEU LEU ASP SEQRES 16 A 248 SER VAL GLN PRO ILE ALA ARG GLU LEU HIS GLN PHE ALA SEQRES 17 A 248 PHE ASP LEU LEU ILE LYS SER HIS MET VAL SER VAL ASP SEQRES 18 A 248 PHE PRO GLU MET MET ALA GLU ILE ILE SER VAL GLN VAL SEQRES 19 A 248 PRO LYS ILE LEU SER GLY LYS VAL LYS PRO ILE TYR PHE SEQRES 20 A 248 HIS HET ZK5 A1918 27 HET PO4 A1919 5 HETNAM ZK5 9ALPHA-FLUOROCORTISOL HETNAM PO4 PHOSPHATE ION FORMUL 2 ZK5 C21 H29 F O5 FORMUL 3 PO4 O4 P 3- FORMUL 4 HOH *106(H2 O) HELIX 1 1 PRO A 671 GLU A 681 1 11 HELIX 2 2 SER A 696 ALA A 721 1 26 HELIX 3 3 GLY A 724 LEU A 728 5 5 HELIX 4 4 HIS A 729 ASN A 758 1 30 HELIX 5 5 ASN A 771 SER A 778 1 8 HELIX 6 6 MET A 780 LEU A 797 1 18 HELIX 7 7 THR A 800 PHE A 813 1 14 HELIX 8 8 ASN A 823 CYS A 844 1 22 HELIX 9 9 SER A 851 SER A 884 1 34 HELIX 10 10 HIS A 885 VAL A 887 5 3 HELIX 11 11 PRO A 892 GLN A 902 1 11 HELIX 12 12 GLN A 902 SER A 908 1 7 SHEET 1 AA 2 LEU A 762 ALA A 765 0 SHEET 2 AA 2 LEU A 768 PHE A 770 -1 O LEU A 768 N PHE A 764 SHEET 1 AB 2 ILE A 815 PRO A 817 0 SHEET 2 AB 2 VAL A 911 PRO A 913 -1 O LYS A 912 N ILE A 816 SITE 1 AC1 7 SER A 696 PHE A 697 LYS A 777 ARG A 779 SITE 2 AC1 7 SER A 853 HOH A2043 HOH A2105 SITE 1 AC2 12 HIS A 701 LEU A 704 ASN A 705 LEU A 707 SITE 2 AC2 12 GLN A 711 ARG A 752 PHE A 764 PHE A 876 SITE 3 AC2 12 ALA A 877 LEU A 880 PHE A 891 HOH A2104 CRYST1 56.350 66.230 73.050 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017746 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015099 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013689 0.00000 MASTER 260 0 2 12 4 0 5 6 0 0 0 20 END